Medicinal Chemistry and Biotechnology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500 007, India.
Academy of Scientific and Innovative Research (AcSIR), New Delhi, India.
Appl Microbiol Biotechnol. 2018 Feb;102(3):1241-1250. doi: 10.1007/s00253-017-8696-4. Epub 2017 Dec 21.
Streptomyces sp. RAB12 having potential to produce novel actinomycin group compounds was isolated from soil samples collected from CSIR-Indian Institute of Chemical Technology, Hyderabad, India, garden premises using International Streptomycetes Project (ISP) protocols. The 16S rRNA sequence of the strain RAB12 exhibited identity with Streptomyces sp. 13647M and the sequence was deposited in NCBI under the accession number KY 203650 while the strain RAB12 was deposited in The Microbial Type Culture Collection and Gene Bank (MTCC) with accession number MTCC 12747. Cell-free extract of this novel strain revealed two bioactive principles viz., RSP 01 and RSP 02. HR-MS analysis indicated a molecular mass of 1269.61 and 1270.63 m/z g/mol for RSP 01 and RSP 02, respectively. Proton H, C NMR, 2D NMR and mass spectroscopy analysis revealed a similar fingerprint to that actinomycin D except for a peak at δH3.59 J (H NMR) and δ 208.88 (C NMR) for RSP 01 compound suggesting the presence of keto carbonyl at 5-oxo position on the proline moiety which is absent in actinomycin D. Purified RSP 02 depicted a similarity with RSP 01 except a peak in the H proton NMR at δH 3.81 J. HR-ESI mass spectra confirmed the molecular formulae for RSP 01 and RSP 02 as CHNO and CHNO, respectively. Antimicrobial activity profile revealed higher antimicrobial activity against bacterial strains (Pseudomonas aeruginosa, Micrococcus luteus, Staphylococcus aureus, Salmonella typhi, and Bacillus subtilis) and Candida albicans compared to standard actinomycin D. MIC and MBC for RSP 01 were observed to be 0.0039 and 0.0078 (μg/ml) against C. albicans, while for actinomycin D, it was found to be 0.031 and 0.62 (μg/ml), respectively indicating a tenfold higher potency. Thus, these RSP 01 and RSP 02 compounds from Streptomyces sp. RAB12 may be promising candidates for industrial and clinical applications.
从印度海得拉巴 CSIR-印度化学技术研究所的土壤样本和花园场所，使用国际链霉菌项目（ISP）方案分离出具有产生新型放线菌素族化合物潜力的链霉菌属 RAB12。菌株 RAB12 的 16S rRNA 序列与链霉菌属 13647M 具有相同的身份，该序列已在 NCBI 中以 KY203650 登录号进行了存储，而 RAB12 菌株则在微生物类型培养物收集和基因银行（MTCC）中以 MTCC12747 的登录号进行了存储。该新型菌株的无细胞提取物中揭示了两种生物活性物质，RSP01 和 RSP02。高分辨质谱分析表明，RSP01 和 RSP02 的分子量分别为 1269.61 和 1270.63 m/zg/mol。质子 H、C NMR、2D NMR 和质谱分析显示，除了 RSP01 化合物的 δH3.59J（H NMR）和 δ208.88（C NMR）峰外，与放线菌素 D 的指纹图谱相似，表明脯氨酸部分 5- 酮羰基的存在，而放线菌素 D 中不存在。纯化的 RSP02 与 RSP01 相似，除了 H 质子 NMR 中的 δH3.81J 峰外。高分辨电喷雾电离质谱（HR-ESI-MS）确认 RSP01 和 RSP02 的分子式分别为 CHNO 和 CHNO。抗菌活性谱显示，与标准放线菌素 D 相比，RSP01 和 RSP02 对细菌菌株（铜绿假单胞菌、藤黄微球菌、金黄色葡萄球菌、伤寒沙门氏菌和枯草芽孢杆菌）和白色念珠菌具有更高的抗菌活性。RSP01 对白色念珠菌的 MIC 和 MBC 分别为 0.0039 和 0.0078（μg/ml），而放线菌素 D 的 MIC 和 MBC 分别为 0.031 和 0.62（μg/ml），表明其效力提高了十倍。因此，RSP01 和 RSP02 化合物可能是来自链霉菌属 RAB12 的有前途的工业和临床应用候选物。
